Evaluation of Drug Resistance in the Tamoxifen-treated MKN-45 Gastric Cancer Cell Line via the Epithelial-mesenchymal Transition Signaling Pathway
- PMID: 39006197
- PMCID: PMC11240059
- DOI: 10.22088/IJMCM.BUMS.12.4.361
Evaluation of Drug Resistance in the Tamoxifen-treated MKN-45 Gastric Cancer Cell Line via the Epithelial-mesenchymal Transition Signaling Pathway
Abstract
One of the major challenges in gastric cancer (GC) chemotherapy is the phenomenon of multi-drug resistance (MDR). The epithelial-mesenchymal transition (EMT) and its key molecules, transforming growth factor-β (TGFβ) and SMAD2, play a central role in MDR occurrence. Tamoxifen (TAM), a triphenylethylene derivative, can overcome MDR in human gastric cancers. The aim of this study was to investigate the effect of TAM on 5-FU resistance of GC by suppressing the TGFβ1/SMAD2 signaling pathway and EMT. The MKN-45 cell line was subjected to treatment with 5-FU, TAM and a combination of both. The MTT assay was used to investigate the cytotoxic effects of 5-FU and TAM, and the DNA laddering technique was used to assess DNA fragmentation and apoptosis. Real-time RT-PCR examined the change in gene expression in EMT-related genes (SNAI2, VIM, TGFβ1 and SMAD2). The results of the present study indicated that not only TAM treatment significantly decreased the IC50 of 5-FU (P≤0.05), but also the addition of TAM to 5-FU induced apoptosis in the MKN-45 cell line. Treatment with TAM and 5-FU significantly inhibited TGFβ1 and TGFβ1-induced expression of EMT markers (VIM and SNAI2) in MKN-45 cells (P≤0.05). The reduction of TGFβ1 targets downstream of the SMAD2 signaling pathway reversed the process of EMT and significantly increased the sensitivity of MKN-45 cells to 5-FU. The results of the present study suggested that reversal of EMT-mediated MDR via the TGFβ1/SMAD signaling pathway using TAM may be a potential new therapeutic strategy to overcome chemoresistance to 5-FU during GC chemotherapy.
Keywords: Epithelial-mesenchymal transition; TGFβ1/ SMAD2 signaling pathway; drug resistance; Tamoxifen; gastric cancer.
© The Author(s).
Figures



Similar articles
-
Sensitization of Gastric Cancer Cells to 5-FU by MicroRNA-204 Through Targeting the TGFBR2-Mediated Epithelial to Mesenchymal Transition.Cell Physiol Biochem. 2018;47(4):1533-1545. doi: 10.1159/000490871. Epub 2018 Jun 21. Cell Physiol Biochem. 2018. PMID: 29940566
-
Notch prevents transforming growth factor-beta-assisted epithelial-mesenchymal transition in cultured limbal progenitor cells through the induction of Smad7.Mol Vis. 2014 Apr 25;20:522-34. eCollection 2014. Mol Vis. 2014. PMID: 24791137 Free PMC article.
-
microRNA-33a prevents epithelial-mesenchymal transition, invasion, and metastasis of gastric cancer cells through the Snail/Slug pathway.Am J Physiol Gastrointest Liver Physiol. 2019 Aug 1;317(2):G147-G160. doi: 10.1152/ajpgi.00284.2018. Epub 2019 Apr 3. Am J Physiol Gastrointest Liver Physiol. 2019. PMID: 30943047
-
Low-dose eribulin mesylate exerts antitumor effects in gastric cancer by inhibiting fibrosis via the suppression of epithelial-mesenchymal transition and acts synergistically with 5-fluorouracil.Cancer Manag Res. 2018 Aug 15;10:2729-2742. doi: 10.2147/CMAR.S167846. eCollection 2018. Cancer Manag Res. 2018. PMID: 30147370 Free PMC article.
-
Hyaluronan-mediated motility receptor confers resistance to chemotherapy via TGFβ/Smad2-induced epithelial-mesenchymal transition in gastric cancer.FASEB J. 2019 May;33(5):6365-6377. doi: 10.1096/fj.201802186R. Epub 2019 Feb 25. FASEB J. 2019. PMID: 30802150
References
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous